Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P434: Joint Inflammatory Bowel Disease–Obstetric clinics: outcomes in 95 pregnancies at a tertiary centre over a 3-year periodECCO '17 Barcelona
Year: 2017
Authors:

Chew T.S.*1, Carmichael M.S.1, Hoare T.W.2, Waugh J.3, Gunn M.C.1

1Royal Victoria Infirmary, Department of Gastroenterology, Newcastle upon Tyne, United Kingdom 2Royal Victoria Infirmary, Department of Radiology, Newcastle upon Tyne, United Kingdom 3Royal Victoria Infirmary, Department of Obstetric and Gynaecology, Newcastle upon Tyne, United Kingdom

P435: The mean corpuscular volume flow – prognostic value for inflammatory bowel disease under thiopurine treatmentECCO '17 Barcelona
Year: 2017
Authors:

Roseira J.*1, Tavares de Sousa H.1, Marreiros A.2, Queiros P.1, Vaz A.M.1, Gago T.1, Contente L.1, Guerreiro H.1

1Algarve Hospital Centre, Gastroenterology, Algarve, Portugal 2Universidade do Algarve, Biomedical Science, Algarve, Portugal

P436: Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practiceECCO '17 Barcelona
Year: 2017
Authors:

Jimenez M.*1, Sierra-Ausin M.1, Cano N.1, Suarez P.1, Fernandez-Gundin M.1, Saez-Villafañe M.2, Monteserin L.1, Molina G.1, Reyes N.1, Viso D.1, Jorquera F.1

1Hospital Universitario de Leόn, Gastroenterology, Leόn, Spain 2Hospital Universitario de Leόn, Pharmacoloy, Leόn, Spain

P437: Autologous hematopoietic stem cell transplantation for refractory Crohn's disease: predictive factors of relapseECCO '17 Barcelona
Year: 2017
Authors:

Lόpez García A.*1, Rovira M.2, Jauregui Amezaga A.1, Marin P.3, Barastegui R.1, Salas A.1, Feu F.1, Elizalde J.1, Fernández-Avilés F.2, Martínez C.4, Gutierrez G.2, Rosiñol L.2, Carreras E.2, Urbano A.2, Lozano M.3, Cid J.3, Suárez-Lledό M.2, Masamunt M.C.1, Comas D.1, Giner A.1, Gallego M.1, Alfaro I.1, Ordás I.1, Panés J.1, Ricart E.1

1Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain 2Hospital Clinic Barcelona, Hematology, Barcelona, Spain 3Hospital Clinic Barcelona, Biomedic Diagnostic Center, Barcelona, Spain 4Hospital Clinic Barcelona, Gynecology, Barcelona, Spain

P438: Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Van de Vondel S.*1, Baert F.2, Reenaers C.3, Bossuyt P.4, Hindryckx P.5, Vanden Branden S.6, Amininejad L.7, Dewint P.8, Rahier J.F.9, Ferrante M.1 Belgian IBD Research and Development

1University Hospitals Leuven, Dept of Gastroenterology, Leuven, Belgium 2AZ Delta, Dept of Gastroenterology, Roeselare, Belgium 3University Hospital CHU of Liège, Dept of Gastroenterology, Liège, Belgium 4Imelda Hospital, Dept of Gastroenterology, Bonheiden, Belgium 5Ghent University Hospital, Dept of Gastroenterology, Gent, Belgium 6Onze-Lieve-Vrouw Hospital, Dept of Gastroenterology, Aalst, Belgium 7Erasme Hospital, Université Libre de Bruxelles, Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, Belgium 8AZ Maria Middelares, Dept of Gastroenterology, Gent, Belgium 9CHU Dinant Godinne, UCL Namur, Dept of Gastroenterology, Yvoir, Belgium

P439: Diagnosis and management of latent and active tuberculosis in the context of biologic therapy in inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Thi A.A.*1, Bouri S.1, Wolfson P.1, Owen L.1, Abbara A.2, John L.2, Davidson R.2, Hart A.1

1St Mark's Hospital, London, United Kingdom 2Northwick Park Hospital, London, United Kingdom

P440: Therapeutic drug monitoring of infliximab for the management of loss of response in inflammatory bowel disease: an observational multicenter studyECCO '17 Barcelona
Year: 2017
Authors:

Pugliese D.*1, Armuzzi A.1, Panici Tonucci T.1, Tolusso B.2, Felice C.1, Papa A.1, Cantoro L.3, Balestrieri P.4, Civitelli F.5, Bertani L.6, Kohn A.3, Cicala M.4, Viola F.5, Costa F.6, Rapaccini G.L.1, Guidi L.1

1Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, UOC Gastroenterologia Presidio Columbus, Rome, Italy 2Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli, UOC Reumatologia Presidio Columbus, Rome, Italy 3AO San Camillo Forlanini, IBD Unit, Rome, Italy 4Campus BioMedico, University of Rome, Department of Gastroenterology, Rome, Italy 5Università La Sapienza, UOC Pediatric Gastroenterology, Rome, Italy 6AOU Pisana, UOC Gastroenterologia Universitaria, Pisa, Italy

P441: Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label studyECCO '17 Barcelona
Year: 2017
Authors:

Mao R.*1, He Y.1, Ben-Horin S.2, Chen M.-h.1

1First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China 2Sheba Medical Center, Tel-aviv, Israel

P442: Incidence of pneumonia and other respiratory tract infections with vedolizumab treatment for inflammatory bowel disease: clinical trial experienceECCO '17 Barcelona
Year: 2017
Authors:

Feagan B.1, Bhayat F.*2, Khalid J.M.3, Palo W.4, Blake A.5, Shetzline M.6, Travis S.7

1Robarts Research Institute, University of Western Ontario, Robarts Clinical Trials, London, Canada 2Takeda Development Centre Europe Ltd, Global Pharmacovigilance, London, United Kingdom 3Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom 4Takeda Development Center Americas, Inc., Global Statistics and Statistical Programming, Deerfield, United States 5Takeda Development Center Europe Ltd, Global Pharmacovigilance, London, United Kingdom 6Takeda Pharmaceuticals International Co., Clinical Science, GI, Cambridge, United States 7University of Oxford, Translational Gastroenterology Unit, Nuffield Department of Medicine, Oxford, United Kingdom

P443: Systematic review of internet decision making resources for patients considering surgery for ulcerative colitisECCO '17 Barcelona
Year: 2017
Authors:

Baker D.*1, Marshall J.1, Lee M.2, Jones G.3, Brown S.2, Lobo A.4

1University of Sheffield Medical School, Sheffield, United Kingdom 2Sheffield Teaching Hospitals, General Surgery, Sheffield, United Kingdom 3Leeds Beckett University, Leeds, United Kingdom 4Sheffield Teaching Hospitals, Academic Unit of Gastroenterology, Sheffield, United Kingdom

P444: Does one size truly fit all? Co-prescription of allopurinol and thiopurine therapy results in variation of TGNs outside the therapeutic range in more than half of patientsECCO '17 Barcelona
Year: 2017
Authors:

Johnston E.*1, Warner B.1, Fong S.1, Arenas-Hernandez M.2, Marinaki A.2, Anderson S.1, Sanderson J.1, Irving P.1

1IBD Centre, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom 2Viapath Pathology Services, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom

P445: Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's disease undergoing right hemicolectomy with ileocolonic anastomosisECCO '17 Barcelona
Year: 2017
Authors:

Schils N.*1, De Buck van Overstraeten A.2, Vermeire S.1, Van Assche G.1, Wolthuis A.2, D'Hoore A.2, Ferrante M.1

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium 2University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium

P446: Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54ECCO '17 Barcelona
Year: 2017
Authors:

Sandborn W.J.1, Rutgeerts P.2, Zhang H.3, Adedokun O.J.3, Xu S.3, Shraim R.3, Marano C.*3

1University of California, San Diego, United States 2University Hospital, Gasthuisberg, Leuven, Belgium 3Janssen Research & Development, LLC, Spring House, United States

P447: Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Pauwels R.W.M., De Vries A.C., Van der Woude C.J.

Erasmus MC, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands

P448: Biologic therapy and immunodulators are associated with decreased risk of cardiovascular events in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Fumery M.*1, Singh A.2, Khera R.3, Prokop L.4, Curtis J.5, Sandborn W.6, Singh S.6

1Amiens University Hospital, Department of Gastroenterology and Hepatology, Amiens, France 2University of California San Diego, La Jolla, Rheumatology, San Diego, United States 3University of Texas Southwestern Medical Center, Divsion of Cardiology, Dallas, United States 4Mayo Clinic, Rochester, United States 5University of Alabama, Clinical immunology and Rheumatology, Alabama, United States 6University of California San Diego, Department of Gastroenterology, La Jolla, United States

P449: Patient support program for adalimumab-treated patients with Crohn's disease in Brazil: impact on patients' adherence and persistenceECCO '17 Barcelona
Year: 2017
Authors:

Teich V.*1, Arinelli R.1, Gulart A.1, Chaves L.2, Garg V.2, Skup M.2

1Sense Company, São Paulo, Brazil 2AbbVie Inc., North Chicago, United States

P450: Reliability assessment of endoscopic scoring tools using central video review of colonoscopies in paediatric patients with ulcerative colitis: data from the Canadian Children IBD NetworkECCO '17 Barcelona
Year: 2017
Authors:

Carman N.*1, Huynh H.2, Walsh C.M.1, Ricciuto A.1, Mouzaki M.1, Crowley E.1, Church P.C.1, Walters T.D.1

1The Hospital for Sick Children, University of Toronto, Gastroenterology Department, Toronto, Canada 2University of Alberta, Edmonton, Canada

P451: Compound IBD patient profiles are related to specific information needs – an Israeli national surveyECCO '17 Barcelona
Year: 2017
Authors:

Daher S.*1, Benson A.1, Walker J.2, Hammerman O.1, Khoury T.1, Naftali T.3,4, Eliakim R.4,5, Ben-Bassat O.4,6, Bernstein C.2, Israeli E.1

1Hadassah-Hebrew university medical center, Institute of gastroenterology and liver diseases, Jerusalem, Israel 2University of Manitoba, IBD Clinical and Research Centre, Winnipeg, Canada 3Meir medical center, Department of Gastroenterology and Hepatology, Kfar Saba, Israel 4Tel-Aviv university, Sackler school of medicine, Tel aviv, Israel 5Sheba medical center, Department of Gastroenterology, Ramat Gan, Israel 6Rabin medical center, IBD center, Petach Tekva, Israel

P452: Silent anaemia predicts treatment change in patients with Crohn's disease in clinical remissionECCO '17 Barcelona
Year: 2017
Authors:

Soufleris K., Kafalis N., Katsoula A., Chatzinakos G., Grammatikos N., Giouleme O.

Ippokration General Hospital of Thessaloniki, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece

P453: Efficacy of therapeutic drug monitoring of anti-TNF therapy in the control of patients with inflammatory bowel diseaseECCO '17 Barcelona
Year: 2017
Authors:

Bernardo S., Fernandes S., Gonçalves A.R., Baldaia C., Valente A., Moura Santos P., Correia L., Velosa J.

Hospital Santa Maria, CHLN, Department of Gastroenterology and Hepatology, Lisbon, Portugal